FY2024 Earnings Estimate for MIRM Issued By Leerink Partnrs

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($1.63) for the year, up from their previous estimate of ($1.93). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.81) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals’ Q4 2024 earnings at ($0.28) EPS and FY2025 earnings at ($0.99) EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. During the same period last year, the firm posted ($0.57) EPS. The company’s revenue was up 89.4% on a year-over-year basis.

Several other brokerages have also recently issued reports on MIRM. Cantor Fitzgerald lifted their target price on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Evercore ISI upped their price objective on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday. Citigroup upped their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $57.73.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $44.50 on Friday. The company has a market cap of $2.14 billion, a P/E ratio of -22.03 and a beta of 1.16. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $48.89. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.09 and a current ratio of 3.34. The firm’s fifty day moving average is $40.12 and its two-hundred day moving average is $36.07.

Insider Activity at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00. Following the completion of the sale, the senior vice president now owns 2,426 shares in the company, valued at $114,264.60. This trade represents a 50.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 22.87% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its position in shares of Mirum Pharmaceuticals by 34.2% in the 1st quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock worth $69,470,000 after purchasing an additional 704,659 shares during the period. Candriam S.C.A. purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth $17,384,000. Loomis Sayles & Co. L P bought a new position in Mirum Pharmaceuticals in the third quarter worth about $19,473,000. Clearbridge Investments LLC lifted its position in shares of Mirum Pharmaceuticals by 165.5% during the second quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after buying an additional 436,349 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Mirum Pharmaceuticals by 37.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after buying an additional 432,824 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.